← Kyverna Therapeutics, Inc. (KYTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Kyverna Therapeutics, Inc. (KYTX)
Biological Products, (No Diagnostic Substances) · market cap $440M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Kyverna Therapeutics (KYTX) is a clinical-stage cell therapy company focused on autoimmune diseases, with 129 employees and a ~$540M market cap at ~$8.89/share. Its lead program is KYV-101, an anti-CD19 CAR-T therapy being evaluated across Lupus Nephritis, Systemic Sclerosis, and Multiple Sclerosis, alongside a Phase 3 Lupus Nephritis trial and a Phase 3 Myasthenia Gravis program. The company's most acute near-term issue is a reported cash position of $32.2M with a runway of only ~2.3 months, creating severe financing risk ahead of multiple pending readouts.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 3 · Standard of Care Treatmentimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| KYV-101 anti-CD19 CAR-T cell therapy | Phase 2 | Lupus Nephritis |
| Standard lymphodepletion regimen | Phase 3 | Lupus Nephritis |
| Anti-CD20 mAB | Phase 2 | Multiple Sclerosis, Primary Progressive |
| Standard of Care Treatment | Phase 3 | Myasthenia Gravis |
| KYV-101 | Phase 3 | Systemic Sclerosis |
Price & technical context
3-month
-31.1%
6-month
-28.9%
12-month
+5.7%
52-wk range
$5.41–$11.25
vs 50-day MA
-18.2%
vs 200-day MA
-24.5%
Realized vol
97.6%
Max drawdown
-75.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KYTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.